Have questions? Visit https://www.reddit.com/r/SNPedia

rs8099917

From SNPedia

Orientationplus
Stabilizedplus
Geno Mag Summary
(G;G) 3 lower odds of responding to PEG-IFNalpha/RBV treatment
(G;T) 2 Moderately lower odds of responding to PEG-IFNalpha/RBV treatment
(T;T) 0 common
ReferenceGRCh38 38.1/141
Chromosome19
Position39252525
is asnp
is mentioned by
dbSNPrs8099917
ebirs8099917
HLIrs8099917
Exacrs8099917
Varsomers8099917
Maprs8099917
PheGenIrs8099917
hapmaprs8099917
1000 genomesrs8099917
hgdprs8099917
ensemblrs8099917
gopubmedrs8099917
geneviewrs8099917
scholarrs8099917
googlers8099917
pharmgkbrs8099917
gwascentralrs8099917
openSNPrs8099917
23andMers8099917
23andMe allrs8099917
SNP Nexus

SNPshotrs8099917
SNPdbers8099917
MSV3drs8099917
GWAS Ctlgrs8099917
GMAF0.1382
Max Magnitude3
? (G;G) (G;T) (T;T) 28
23andMe blog

rs8099917(C) less likely to respond to Hepatitis C treatment.

rs12979860(C;C) better able to become naturally Hepatitis C virus-free. rs12980275(A) usually corresponds to the rs12979860(C)

GWAS snp
PMID [PMID 19749758]
Trait Response to Hepatitis C treatment
Title IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
Risk Allele G
P-val 9E-9
Odds Ratio 1.98 [1.57-2.52]
GWAS snp
PMID [PMID 19749757]
Trait Response to Hepatitis C treatment
Title Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
Risk Allele G
P-val 3E-32
Odds Ratio 27.10 [14.6-50.3]
OMIM607402
DescINTERLEUKIN 28B; IL28B
Variant
Relatedalso
GWAS snp
PMID [PMID 20060832]
Trait Chronic Hepatitis C infection
Title Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study
Risk Allele G
P-val 6E-9
Odds Ratio 2.31 [1.74-3.06]


[PMID 20576307] A common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients

[PMID 20803561OA-icon.png] Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection


[PMID 21068134] HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

OMIM609532
Desc
Variant
Relatedalso


[PMID 21382156] Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment


[PMID 21384511] Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

GWAS snp
PMID [PMID 21228123]
Trait
Title IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
Risk Allele G
P-val 1E-20
Odds Ratio 3.0000 [2.4-3.8]


[PMID 21618576] Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus


[PMID 21722179] Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data


[PMID 21390311OA-icon.png] Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms


[PMID 21914076] IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma


[PMID 21987611OA-icon.png] IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients


[PMID 21994136OA-icon.png] Ultra-Rapid Virological Response, Young Age, Low ?-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-?(2a) Monotherapy


[PMID 22032680] Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region


[PMID 22052088] Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection


[PMID 22087138OA-icon.png] Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B


[PMID 22118055] Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy


[PMID 22174846OA-icon.png] Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients


[PMID 22234924] Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection


[PMID 22257210] A Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction for the Detection of rs8099917 IL28B Genotype


[PMID 22336553] [Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection]


[PMID 22336134OA-icon.png] Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus Type-1 mono-infection and Co-infection with hepatitis C Virus


[PMID 22356575] The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy


[PMID 22374338] Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis


[PMID 21745312] Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy


[PMID 22521237] Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment


[PMID 22550527OA-icon.png] Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response


[PMID 22156487] Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy


[PMID 22193282] Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.


[PMID 22649509OA-icon.png] IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population


[PMID 22591106] Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.


[PMID 22387386] Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.


[PMID 22713131OA-icon.png] Prediction of response to pegylated-interferon-¿ and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype


[PMID 20434452] Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.


[PMID 20648473] Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.


[PMID 20708617] Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.


[PMID 20728570] Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C.


[PMID 21048934OA-icon.png] IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.


[PMID 21080244] The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.


[PMID 21112657] Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.


[PMID 21112660] Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.


[PMID 21145800] IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.


[PMID 21145807] Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.


[PMID 21254157] Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.


[PMID 21274371OA-icon.png] Peginterferon and ribavirin treatment for hepatitis C virus infection.


[PMID 21321200OA-icon.png] Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.


[PMID 21325786] Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.


[PMID 21354446] IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.


[PMID 21360545] Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.


[PMID 21374656] IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.


[PMID 21389156OA-icon.png] The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.


[PMID 21466653] Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.


[PMID 21501223] Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.


[PMID 21503910] Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.


[PMID 21567424] Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.


[PMID 21613433OA-icon.png] Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients.


[PMID 21692944] IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.


[PMID 21703176] Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.


[PMID 21704279OA-icon.png] Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.


[PMID 21721028] Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.


[PMID 21739446] Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.


[PMID 21879313] Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.


[PMID 21889215] IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis.


[PMID 21898478] Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.


[PMID 21900787] A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.


[PMID 21907615] Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.


[PMID 21911885] Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.


[PMID 22013224OA-icon.png] IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.


[PMID 22095536] Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.


[PMID 22098416] IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.


[PMID 22098610] Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.


[PMID 22180014] IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.


[PMID 22180419OA-icon.png] IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.


[PMID 22192885] Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.


[PMID 22209781] Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese.


[PMID 22239510] Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.


[PMID 22245236] Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection.


[PMID 22310928] Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma.


[PMID 22314430] IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.


[PMID 22325058] Association of polymorphisms in interleukin-18 and interleukin-28B with Hepatitis B recurrence after liver transplantation in Chinese Han population.


[PMID 22329371] IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection.


[PMID 22350701] IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.


[PMID 22382633] Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients.


[PMID 22404723] Lymphotropic hepatitis C virus has an interferon-resistant phenotype.


[PMID 22432893] IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation.


[PMID 22438096] Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.


[PMID 22441534] Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.


[PMID 22505587] Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.


[PMID 22537149] Development of new IL28B genotyping method using Invader Plus assay.


[PMID 22613000] Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.


[PMID 22664181] A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome.


[PMID 22966241OA-icon.png] The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C


GET Evidence
rs8099917
aa_change
aa_change_short
impact pathogenic
qualified_impact Insufficiently evaluated pathogenic
overall_frequency 0.15625
summary



[PMID 23118765OA-icon.png] Hepatitis C virus clearance after discontinuation of pegylated interferon alpha-2a monotherapy in a child


[PMID 23133602OA-icon.png] Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants


[PMID 23149444] Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment


[PMID 23189850] [Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C]


[PMID 23252241] [Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C]


[PMID 23442843] Role of Interleukin 28B-related Gene Polymorphisms in Chronic Hepatitis C and the Response to Antiviral Therapy in Koreans


[PMID 23490371] Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients


[PMID 23029188OA-icon.png] Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis


[PMID 23109451] IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population


[PMID 23020144] Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy


[PMID 23782163] Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China


[PMID 23860735] Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C


[PMID 23866096] The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients


[PMID 23231085] IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4


[PMID 23426277] Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C


[PMID 24130799OA-icon.png] microRNA-122 Abundance in Hepatocellular Carcinoma and Non-Tumor Liver Tissue from Japanese Patients with Persistent HCV versus HBV Infection


[PMID 24192751] Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT


[PMID 24197875OA-icon.png] Utility of Telaprevir-Resistant Variant Detection for Prediction of Treatment Efficacy in HCV Genotype 1


[PMID 23197895OA-icon.png] Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes


[PMID 24303092OA-icon.png] IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase


[PMID 24355007] Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients


[PMID 24477330] A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy


[PMID 24553484] Impact of Comorbid Hepatic Steatosis on Treatment of Chronic Hepatitis C in Japanese Patients and the Relationship with Genetic Polymorphism of IL28B, PNPLA3 and LDL Receptor


[PMID 24620020] Immunomodulatory function of interleukin-28B during primary infection with Cytomegalovirus


[PMID 24621321OA-icon.png] Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-alpha-2a with ribavirin therapy: a case report


[PMID 22536875] Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.


[PMID 22612669] Efficacy of reduction therapy of natural human beta-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.


[PMID 22626609] Factors that predict response of patients with hepatitis C virus infection to boceprevir.


[PMID 22742526] Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.


[PMID 22806754] Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.


[PMID 22814458OA-icon.png] Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping.


[PMID 22842190] Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-alpha plus ribavirin: a meta-analysis.


[PMID 22850127] The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C.


[PMID 22863264] Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.


[PMID 22863269] Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.


[PMID 22889955] Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.


[PMID 22898703] Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.


[PMID 22913807] Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel.


[PMID 22930507] Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.


[PMID 23103287] IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.


[PMID 23135173] Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.


[PMID 23142377] Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.


[PMID 23145987] Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation.


[PMID 23154876] Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.


[PMID 23161429] Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.


[PMID 23213063] Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus.


[PMID 23216931] Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-alpha plus ribavirin in patients with chronic hepatitis C.


[PMID 23246359] Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.


[PMID 23266640] Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians.


[PMID 23296193] IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients.


[PMID 23297176] Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.


[PMID 23314745OA-icon.png] Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.


[PMID 23333445OA-icon.png] Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation.


[PMID 23356752] Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.


[PMID 23449268] HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.


[PMID 23455512OA-icon.png] IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test.


[PMID 23486666] 'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.


[PMID 23490377] Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study.


[PMID 23490380] An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.


[PMID 23560893] Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.


[PMID 23565619] IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.


[PMID 23586360] Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.


[PMID 23591768OA-icon.png] Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.


[PMID 23611115] Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis.


[PMID 23611467] CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation.


[PMID 23613588OA-icon.png] Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.


[PMID 23689988] Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.


[PMID 23689989] IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.


[PMID 23730840] Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.


[PMID 23777929] Searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease.


[PMID 23829453] Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.


[PMID 24750345] ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type


[PMID 24379268] [The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections]


[PMID 24914551OA-icon.png] Impact of Host IL28B rs12979860, rs8099917 in Interferon Responsiveness and Advanced Liver Disease in Chronic Genotype 3 Hepatitis C Patients


[PMID 24929144] KIR3DL1-HLA-Bw4 Combination and IL28B Polymorphism Predict Response to Peg-IFN and Ribavirin with and without Telaprevir in Chronic Hepatitis C


[PMID 24379617OA-icon.png] Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients


[PMID 25032184OA-icon.png] No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients


[PMID 24204859OA-icon.png] Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection


[PMID 24117654] Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b


[PMID 25233462OA-icon.png] IL28B Gene Polymorphism SNP rs8099917 Genotype GG Is Associated with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in HTLV-1 Carriers


[PMID 24349054OA-icon.png] No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV


[PMID 25563035OA-icon.png] Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico


[PMID 25652367] IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with Chronic Hepatitis C


[PMID 25664396] Gene polymorphisms of interleukin 28B and the risk to chronic hepatitis B virus infection in Thai


[PMID 25769643] IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis


[PMID 25803108OA-icon.png] Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aboriginals in Canadian HIV-Hepatitis C Co-Infected Individuals


[PMID 25810555OA-icon.png] Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype-1b Hepatitis C Virus


[PMID 25852275OA-icon.png] Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C


[PMID 25863261] COMPARISON OF FOUR METHODS OF GENOTYPING IL28B POLYMORPHISMS IN CHRONIC HEPATITIS C PATIENTS


[PMID 25904097] The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay


[PMID 25907669] Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a


[PMID 26003758] Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients


[PMID 24118788] Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients


[PMID 24924923] The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection


[PMID 25376093OA-icon.png] Association between single-nucleotide polymorphisms and early spontaneous hepatitis B virus e antigen seroconversion in children


[PMID 25503988OA-icon.png] IL-28B is a key regulator of B- and T-cell vaccine responses against influenza


[PMID 26263394OA-icon.png] Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal


[PMID 25938745] IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication


[PMID 26281194] [Impact of interleukin-10 and interleukin-28 gene polymorphisms on the development and course of lupus nephritis]


[PMID 26400298] Association of polymorphism within the interleukin-28 receptor alpha gene, but not in interleukin-28B, with lower urinary tract symptoms (LUTS) in Chinese


[PMID 25661337] Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients


[PMID 26060059] Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment


[PMID 24840315] Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B


[PMID 25312023] IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population


ClinVar
Risk rs8099917(G;G)
Alt rs8099917(G;G)
Reference rs8099917(T;T)
Significance Drug-response
Disease interferons peginterferon alfa-2a
Variation info
Gene
CLNDBN interferons, peginterferon alfa-2a, peginterferon alfa-2b, and ribavirin response - Efficacy peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, and telaprevir response - Efficacy
Reversed 0
HGVS NC_000019.9:g.39743165T>G
CLNSRC PharmGKB Clinical Annotation PharmGKB
CLNACC RCV000211192.1, RCV000211316.1,